Loading search results

Interventions

inetetamab and PD-1 inhibitor combined with chemotherapy.Drug

1. Chemotherapy selected by doctors: albumin bound paclitaxel, vinorelbine, gemcitabine, capecitabine, and aribrin were administered according to clinical routine; 2. The first dose was 8 mg / kg, followed by 6 mg / kg, once every 3 weeks 3. PD-1 inhibitor 200mg D1 every 3 weeks as a cycle Treatment to disease progression or toxicity intolerance, or death from any cause. The efficacy was evaluated every 2 cycles and adverse events were recorded. After 4-6 cycles of treatment, if the patient is intolerable to chemotherapy for any reason, the chemotherapy can be stopped and the combination of inistumab and PD-1 can be continued.

inetetamab and PD-1 inhibitor combined with chemotherapy.

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 75 Years

Sexfemale

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Age: 18-75 years old female patients;
The results showed that HER-2 was positive at least once in patients with recurrent and metastatic breast cancer confirmed by pathology: HER-2 (+ + +) was confirmed by immunohistochemistry; if HER-2 (+ +), fish / CISH was required to confirm HER-2 amplification;

Related Publications (1)

Lv H, Sun T, Ling X, Liu X, Yang J, Zhang M, Niu L, Chen S, Liu Z, Wang C, Sun H, Wang J, Zeng H, Zhao S, Guo L, Feng Y, Zhang Z, Xia Q, Qiu R, Yan M. Inetetamab plus camrelizumab and utidelone for pretreated HER2-positive advanced breast cancer: a prospective, single-arm, phase 2 study. BMC Med. 2026 Jan 27;24(1):108. doi: 10.1186/s12916-026-04643-z.

PMID: 41593669DERIVED

Study Design

Study Type

interventional

Phase

phase 2

Allocation

Masking

NONE

Purpose

TREATMENT

Intervention Model

SINGLE GROUP

Model Details: Patients with advanced HER2 positive breast cancer who had received at least paclitaxel, trastuzumab and TKIs (lapatinib or Pyrotinib) at least in the past were included in this study,Efficacy and safety of combination of inetetamab and PD-1 inhibitor combined with chemotherapy (including albumin bound paclitaxel, vinorelbine, gemcitabine, capecitabine or aribrin).

Sponsor Type

OTHER GOV

Responsible Party

PRINCIPAL INVESTIGATOR

PI Title

Chief Physician

Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

inetetamab and PD-1 inhibitor combined with chemotherapy.

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Related Publications (1)

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

inetetamab and PD-1 inhibitor combined with chemotherapy.

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Related Publications (1)

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations